ArticleBMC cardiovascular disorders2026
Plasma cyclophilin a as a novel predictor of major adverse cardiac events in patients with acute myocardial injury cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclophilin A (CypA) is a multifaceted immunophilin implicated in cardiovascular disease; however, its predictive value for Major Adverse Cardiac Events (MACEs) after acute myocardial injury remains poorly defined. PURPOSE: The study aimed to analyze whether admission Plasma CyPA independently predicts MACEs and to assess its predictive feasibility beyond recognized clinical risk factors.
methodIn this cohort study, 217 adults with an acute myocardial injury diagnosis exhibiting symptom onset within 24 hours and high cardiac troponin 1 were included. Plasma CyPA concentrations were evaluated using enzyme-linked immunosorbent assay. Participants were closely followed up for 6 months to determine MACEs, defined as all-cause mortality, ischemic stroke, nonfatal myocardial infarction, or unexpected heart failure hospitalization. Receiver Operating Characteristic (ROC) analysis, multivariable Cox proportional hazard models, Kaplan-Meier survival curves, and calibration analysis were conducted with adjusted standard covariates.
result30% of participants experienced MACEs, with significantly higher CyPA concentrations among those with events than among those without (median 1.942 vs. 1.026 ng/mL; p < 0.001). CyPA demonstrated good discriminatory ability (AUC 0.755; 95% CI: 0.680-0.830), with an optimal cutoff of 1.651 ng/mL. Higher CyPA levels were associated with significantly lower event-free survival. In multivariable analysis, CyPA remained an independent predictor of MACEs (HR 1.698; 95% CI: 1.462-1.973; p < 0.001). The overall Brier score was 0.158, reinforcing satisfactory precision of absolute risk prediction.
conclusionIntegration of CyPA into the baseline model significantly enhanced analytical performance, improving the C-index from 0.632 to 0.770. These conclusions suggest that CyPA may be a promising biomarker for risk stratification in acute myocardial injury and warrants external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.